GEN-MKT-18-7897-A
Aug 22, 2017 | Blogs, Technology | 0 comments
Scientists and analysts across all fields of testing and research are increasingly challenged by complex samples requiring advanced analytical selectivity. And where LC-MS/MS sensitivity alone is not enough to meet the demands of modern day quantitative performance, Differential Ion Mobility Spectrometry (DMS) has proven to be a valuable addition.
Break Through the Selectivity Barrier of Your LC/MS-MS SeparationsSCIEX offers the most innovative solution with its SelexION® DMS Technology. It is a small, planar mobility cell that is easy to install (in less than 2 minutes), easy-to-use and can significantly increase analytical separation power. No other ion mobility separation tool offers the reproducibility, robustness, and simplicity to deliver highly selective and sensitive quantitative and qualitative analyses, within a UHPLC time scale.
How does SelexION make this possible?The SelexION DMS technology separates ions based on differences in mobility in two different regions of the field dependent mobility curve. Due to its small size, the system can operate with very short ion residence times with optimal performance when using chemical modifiers. The DMS device can also be used in ‘transparent mode’ to allow for maximal workflow flexibility.
Last year, Technology Networks hosted two webinars that featured groundbreaking research utilizing SWATH DIA (data-independent acquisition) for exposomics and metabolomics. Researchers Dr. Vinicius Verri Hernandes from the University of Vienna and Dr. Cristina Balcells from Imperial College London (ICL) demonstrated how a DIA approach can be successfully implemented in small molecule analysis using the ZenoTOF 7600 system. Their innovative approaches highlight the potential of SWATH DIA to enhance the detection and analysis of chemical exposures and metabolites, paving the way for new insights into environmental health and disease mechanisms.
For as long as PFAS persist in the environment, there is no doubt they will persist in our conversations as environmental scientists. Globally, PFAS contamination has been detected in water supplies, soil and even in the blood of people and wildlife. Different countries are at various stages of addressing PFAS contamination and many governments have set regulatory limits and are working on assessing the extent of contamination, cleaning up affected sites and researching safer alternatives.
On average, it takes 10-15 years and 1-2 billion dollars to approve a new pharmaceutical for clinical use. Since approximately 90% of new drug candidates fail in clinical development, the ability to make early, informed and accurate decisions on the safety and efficacy of new hits and leads is key to increasing the chances of success.
Posted by
You must be logged in to post a comment.
Share this post with your network